For US residents only.

Live in the Moment

When you're living with the severe diarrhea and flushing associated with carcinoid syndrome

Important Safety Information:

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring b

... See More
Approved Use:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and long-term treatment of the profuse watery diarrhea

... See More
learn more about

Sandostatin LAR Depot

Sandostatin LAR Depot works by blocking the production of a number of hormones that can lead to severe diarrhea and flushing associated with carcinoid syndrome. Your doctor will identify if Sandostatin LAR Depot is right for you based on your response to, and how well you tolerate, 2 weeks of treatment with Sandostatin® (octreotide acetate) Immediate-release Injection.

Learn More
learn more about

Sign up for RealSupport

RealSupport is an information and support program specifically designed to help patients diagnosed with severe diarrhea and flushing associated with carcinoid syndrome, to access the materials and tools they need to help understand their disease.

Learn More

Important Safety Information:

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor.

Before taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common side effects: Most patients experience side effects at some time. Some common side effects that you may experience include: back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

Please see full Prescribing Information

Approved Use:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated. In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.